STRATA Skin Sciences Reinforces Market Leadership Following Key Litigation Milestones Against LaserOptek

Core Insights - STRATA Skin Sciences, Inc. has successfully strengthened its competitive position through ongoing litigation against LaserOptek America Corp. and its affiliates, with a recent court ruling in its favor [2][3][8] - The company has regained market share by converting dermatology clinics misled by false advertising claims to its XTRAC excimer laser technology, resulting in over $1 million in annualized revenue [5][6][9] - STRATA is poised for growth as the American Medical Association has reaffirmed the exclusive use of excimer lasers under specific CPT codes, allowing for the treatment of a broader range of dermatologic conditions [8][9] Legal Developments - The U.S. District Court for the Eastern District of Pennsylvania partially granted STRATA's motion for a preliminary injunction, adding LaserOptek Korea as a defendant [2] - The court's ruling allows STRATA to hold all responsible parties accountable for false advertising and unfair trade practices under the Lanham Act [2][3] Market Positioning - STRATA has engaged over 20 clinics previously using LaserOptek's Pallas laser, converting them to XTRAC excimer laser users [5][6] - Approximately 1,200 U.S. dermatology clinics currently utilize excimer laser therapy, with 844 of these clinics under STRATA's partnership program [6][8] Partnership Program - STRATA's partnership program is designed for individual clinic owners and includes over 358 clinics owned by private equity-backed national accounts, indicating potential expansion to over 2,000 additional clinics [7][8] - The program offers a fee-per-treatment structure, on-site training, and marketing support, enhancing the attractiveness of STRATA's offerings [12] Future Outlook - The expansion of CPT codes to include up to 30 dermatologic conditions is expected to significantly increase patient access and revenue for STRATA and its partner clinics [9] - The company is committed to defending its market share and ensuring ethical billing practices in collaboration with CMS and private payers [9][10]